TELO:NASDAQTelomir Pharmaceuticals, Inc. Analysis

Telomir Pharmaceuticals (TELO) remains a pre‑clinical biotechnology firm with no revenue, negative earnings per share and modest cash reserves, while carrying a low absolute debt load. The balance sheet shows a high price‑to‑book multiple and a negative return on equity, underscoring the speculative nature of the business.
On the technical side, the stock trades near its short‑term moving average, which sits below the 50‑day and 200‑day averages, signalling a bearish price structure. Momentum indicators are mixed – the RSI hovers around the midpoint, the MACD line is just above its signal line with a small positive histogram, yet the broader trend is still classified as bearish. Volatility is elevated and beta is well above market, while the DCF fair‑value estimate sits far below the current price, suggesting the market may be overvaluing the equity relative to its fundamental outlook.